This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Dr. Reddy's Laboratories
Drug Names(s): amoxicillin
Description: Amoxicillin is a member of the aminopenicillin class of antibiotics. The presence of the amino group in these compounds renders them stable to hydrolysis in gastric fluids, and thus they can be dosed orally unlike many earlier generation penicillin products. Amoxicillin and other aminopenicillins are readily degraded by beta lactamase enzymes produced by many Gram-(+) and Gram-(-) bacteria. For this reason amoxicillin is often combined with the beta lactamase inhibitor clavulanate. The resulting product was developed by GSK under the trade name Augmentin.
Approximately 51 million prescriptions for generic versions of Amoxil, and an additional 20 million prescriptions for generic versions of Augmentin were filled in the US in 2010. Taking these together, amoxicillin was the third most widely prescribed drug in the US by prescription count.
When originally approved, Amoxil exhibited relatively broad spectrum activity against Gram-(+) and Gram-(-) organisms, including Streptococci, Enterococci, Neisseria, many anaerobes, Enterobacteriaceae, E. coli, Proteus mirabilis, Salmonella, Haemophilus influenzae, and Helicobacter pylori. Ensuing years have seen increased amoxicillin resistance, especially among Gram-(-) organisms.
Amoxil was originally developed by GlaxoSmithKline (GSK).
In November 2010, GSK and Dr. Reddy's Laboratories that the companies have signed an agreement to transfer rights for the Augmentin and Amoxil brands in the United States to Dr. Reddy's. GSK will retain the existing rights for these brands outside the United States. Further financial terms and conditions of the agreement have not been disclosed.
In August 2012, GlaxoSmithKline reached agreement to divest the majority of its Classic Brands (25 non-promoted and genericised products) in Australia to Aspen for approximately GBP 172 million in cash. The divested brands include Valtrex, Lamictal, Timentin, Amoxil and Aropax. In December 2012, GlaxoSmithKline completed its divestment of its Classic Brands to Aspen.
Partners: GlaxoSmithKline plc Aspen Pharmacare Holdings Limited
Additional information available to subscribers only: